They selected matrix metalloproteinase-9 (MMP9) as a prognostic marker for pancreatic cancer and possible adjustment to the treatment of diabetes, pancreatic cancer and associated neuropathy. This evidence concerns the gene MMP9 and familial pancreatic carcinoma.